Results 131 to 140 of about 12,008,318 (406)

Aberrantly elevated suprabasin in the bone marrow as a candidate biomarker of advanced disease state in myelodysplastic syndromes [PDF]

open access: gold, 2020
Miroslav Přibyl   +12 more
openalex   +1 more source

Gut microbiota diversity is prognostic in metastatic hormone receptor‐positive breast cancer patients receiving chemotherapy and immunotherapy

open access: yesMolecular Oncology, EarlyView.
In this exploratory study, we investigated the relationship between the gut microbiota and outcome in patients with metastatic hormone receptor‐positive breast cancer, treated in a randomized clinical trial with chemotherapy alone or chemotherapy in combination with immune checkpoint blockade.
Andreas Ullern   +7 more
wiley   +1 more source

PYCR1 inhibition in bone marrow stromal cells enhances bortezomib sensitivity in multiple myeloma cells by altering their metabolism

open access: yesMolecular Oncology, EarlyView.
This study investigated how PYCR1 inhibition in bone marrow stromal cells (BMSCs) indirectly affects multiple myeloma (MM) cell metabolism and viability. Culturing MM cells in conditioned medium from PYCR1‐silenced BMSCs impaired oxidative phosphorylation and increased sensitivity to bortezomib.
Inge Oudaert   +13 more
wiley   +1 more source

Paget's disease of bone [PDF]

open access: yesThe Journal of Bone and Joint Surgery. British volume, 1979
This chapter focuses on Paget's disease of bone. The pathological hallmark of the Paget's bone disease is excessive and disorganized activity of bone that involves both matrix and mineral. There is no idea of its cause and little knowledge of its natural history; however, the biochemical changes produced by the overactive bone justify its inclusion as ...
openaire   +3 more sources

Predictors of response and rational combinations for the novel MCL‐1 inhibitor MIK665 in acute myeloid leukemia

open access: yesMolecular Oncology, EarlyView.
This study characterizes the responses of primary acute myeloid leukemia (AML) patient samples to the MCL‐1 inhibitor MIK665. The results revealed that monocytic differentiation is associated with MIK665 sensitivity. Conversely, elevated ABCB1 expression is a potential biomarker of resistance to the treatment, which can be overcome by the combination ...
Joseph Saad   +17 more
wiley   +1 more source

Paget's Disease of Bone [PDF]

open access: yesNew England Journal of Medicine, 1993
Paget's disease of bone may present with bone pain but is often asymptomatic. Treatment (typically with bisphosphonates) is indicated in patients with pain that is localized to an affected site but not in asymptomatic patients.
openaire   +3 more sources

Primer on the metabolic bone diseases and disorders of mineral metabolism

open access: yesThe Indian journal of medical research, 1994
Part 1 Anatomy and biology of bone matrix and cellular elements: anatomy and ultrastructure of bone bone morphogenesis and embryologic development bone formation - osteoblast lineage cells, growth factors, matrix proteins and the mineralization process ...
R. Goswami
semanticscholar   +1 more source

Liquid biopsy epigenetics: establishing a molecular profile based on cell‐free DNA

open access: yesMolecular Oncology, EarlyView.
Cell‐free DNA (cfDNA) fragments in plasma from cancer patients carry epigenetic signatures reflecting their cells of origin. These epigenetic features include DNA methylation, nucleosome modifications, and variations in fragmentation. This review describes the biological properties of each feature and explores optimal strategies for harnessing cfDNA ...
Christoffer Trier Maansson   +2 more
wiley   +1 more source

Identification of SLC4A2 as a new causal gene for osteopetrosis in human

open access: yesBone Reports, 2021
Jingyi Xue   +3 more
doaj   +1 more source

Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting

open access: yesMolecular Oncology, EarlyView.
CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy